New Pre-Surgery treatment strategy aims to stop rare skin Cancer's return
NCT ID NCT05496036
Summary
This study is testing if giving an immunotherapy drug called pembrolizumab before surgery helps people with a rare and aggressive skin cancer called Merkel cell carcinoma. The goal is to see if this approach shrinks the tumor and, most importantly, reduces the risk of the cancer coming back after surgery. Researchers will enroll about 15 people with early-stage cancer that can be surgically removed to test the safety and effectiveness of this new treatment sequence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.